Immunotherapy in Lung Cancer. Lyudmila Bazhenova, MD Associate Clinical Professor, Moores UCSD Cancer Center
|
|
- Donna Sanders
- 5 years ago
- Views:
Transcription
1 Immunotherapy in Lung Cancer Lyudmila Bazhenova, MD Associate Clinical Professor, Moores UCSD Cancer Center
2 Disclosures No disclosures relevant to this talk
3 Objectives Review immune pathways Immunology 101 Review pitfalls of immunotherapeutic agents irrc Flair phenomenon. Review several agents in development
4 adenocarcinoma SCC Large cell carcinoma NOS Evolution of L. Bazhenova, MD V V V V 4.0 In the works Chemotherapist Vocabulary: NSCLC Visual aid: Unkn, 42% 5% NSCLC Histopathologist Vocabulary: 30% CK 7, CK 20, TTF-1, CK 5/6, p63 Visual aid: Molecular biologist Vocabulary: EGFR, KRAS, ALK, BRAF, C-MET, PI3K, HER2, MAPK 21, MEK, AKT, FISH, PCR.. Visual aid: 100% Budding Immunologist Vocabulary: MEK, 1% THL, CTLA4, MHC, B7, Antigen, TGF, IL-2 Visual aid: PIK3CA, 1% BRAF, 2% FGFR4, 2% HER 2, 2% EML4-ALK, 5% 5% KRAS, 30% EGFR, 15% 60%
5 Current state of the art Several immunotherapy agents are now in phase III trials 1 just completed its accrual, another one is expected to finish in 6 months Increased interest after approval of sipuleucel-t and ipilimumab Patients LOVE this studies. No problems completing accrual
6 Immunotherapeutic strategies Non specific immune stimulants Talactoferrin Toll like receptor agonists Cadi-05 (TRL2 agonist) Anti CTL4 antibodies. Ipilimumab Monoclonal antibodies to tumor antigens Vaccines Dendritic cell vaccines Tumor cell vaccines GM-CSF modified tumor cell vaccine Belagenpumatucel-L Protein/peptide vaccines IDM MAGE A3 vaccine L-BLP25
7
8 [TITLE] Slide courtesy of Raffit Hassan. MD
9 [TITLE] Slide courtesy of Raffit Hassan. MD
10
11 Nov 2009 Feb Started on Phase III Belagenpumatucel-L trial December 2009
12 Tissue biopsy
13 Pseudoprogression Nov 2009 Feb Mar
14 Paradigm shift Traditional chemotherapycytotoxic Targeted therapy-cytostatic for unselected patients Immune therapy-continuum of biological events
15 Continuum of biological events Immune activation and T- cell proliferation Early Clinically measurable antitumor effects mediated by activated immune cells Potential delayed effect on survival Weeks to months Months to years Hoos, JNCI, vol 102, Sep 2010
16 Measuring response a holy grail of clinical trials WHO, RECIST, RECIST 1.1 assume that decrease in the tumor size is an evidence of activity of anticancer agent. Immunotherapy agents do not obey those rules.
17 Response patterns in melanoma patients treated with anti CTLA-4 antibody ipilimumab Immediate response Stable disease with slow, steady decline in total tumor burden Response after initial progression Initial mixed response Wolchok, Clin CancerRes 2009; 15
18 Resected progressing metastatic melanoma lesion in a patient treated with ipilimumab Wolchok, Clin CancerRes 2009; 15
19 Cancer Vaccine Clinical Trial Working Group (CVCTWG) Appearance of measurable clinical activity may take longer for immunotherapeutics Responses can occur after conventional RECIST defined progression Discontinuation of vaccine therapy might not be appropriate for some progressive patients unless the progression is confirmed. Durable stable disease may represent clinical benefit Hoss, J Immunother, 2007, vol 30
20 Immune related response criteria (irrc) Tumor burden= SPD index lesions + SPD new measurable lesions Index lesion New measurable lesion Total sum
21 mwho vs. irrc mwho Criteria irresponse criteria CR PR SD PD All lesions gone SPD of index lesions decreases 50% SPD of index lesions of neither CR, PR or PD New lesions not allowed ircr irpr irsd irpd All lesions gone SPD of index and any new lesions decreases 50% SPD of index and any new lesions neither ircr, irpr or irpd SPD of index lesions increases 25% and/or new lesions develop SPD of index and any new lesions increase 25% New lesions are allowed New lesions allowed Wolchok, Clin CancerRes 2009; 15
22 Summary of irrc Appearance of new lesions no longer automatically signifies progression as in WHO. unless they add to a tumor burden by at least 25% If patient is classified as irpd confirmation of progression is required. Confirmation is done at the discretion of investigator in the context of tumor type, patient overall clinical status The new response patterns appear to be clinically meaningful as they correlate with improved outcomes. Further confirmation of irrc is needed in the prospective clinical trials They are not ready for wide acceptance AND they are not accepted by FDA on immune studies.
23
24 Ipilimumab (Ipi) Fully human monoclonal anti CTLA4 antibody CTLA4 inhibits anti-tumor immunity. Blocking CTLA4 potentiates T cells Improves survival in metastatic melanoma Serious, potentially life threatening immune toxicities Colitis, dermatitis, hepatitis, neuritis. Early diagnosis and prompt treatment of those management is required.
25 [TITLE] Slide courtesy of Raffit Hassan. MD
26 Study design Objectives: To evaluate safety and efficacy of ipilimumab in combination with chemotherapy Primary endpoint irpfs Evaluate 2 different schedules Tumor antigen present before Ipi started (aka give chemotherapy first for 2 cycles) Ipi started at the same time as chemotherapy. Key inclusion criteria Chemotherapy naïve patients with ECOG 0-1 without brain metastases or autoimmune disease Response evaluated by both WHO and irrc Lynch et al, abs #7531 ASCO 2011
27 R A N D O M I Z E Trial CA Study Design 1:1:1 n=204 Arm A IPI + Chemo Concurrent Arm B IPI + Chemo Phased* Arm C Chemo only Placebo Treatment Phase (N=203) C C C C C C IPI IPI IPI IPI p p C C C C C C p p IPI IPI IPI IPI C C C C C C p p p p p p q3w Maintenance Phase IPI IPI p q12w IPI IPI p Followup phase Followup phase Followup phase Chemo: Paclitaxel (175 mg/m 2 )/Carboplatin (AUC=6) IV C: chemotherapy doublet IPI: Ipilimumab (10 mg IV) p: Placebo Note: Steroids were given as premedication. * The term sequential, which was listed in the abstract, is now referred to as phased to more accurately reflect the schedule.
28 Kaplan-Meier Plots of irpfs per irrc Concurrent Schedule Phased Schedule
29 Kaplan-Meier Plot of Interim Overall Survival Concurrent Schedule Phased Schedule
30 Results Concurrent Phased Placebo ir BORR 21% 32% 18% irdcr 70% 86.8% 81.8% irpfs 5.5m 5.7m 4.6m HR P= HR 0.69 P=0.026 OS 11m 11.6m 10m HR P=0.429 HR P=0.104
31 Key Immune-Related Adverse Events Arm A Concurrent IPI + Chemo (N=71) Arm B Phased IPI + Chemo (N=67) N(%) Arm C Placebo Chemo Only (N=65) Total Gr 3 Gr 4 Total Gr 3 Gr 4 Total Gr 3 Gr 4 Any irae 46 (64.8) 13 (18.3) 1 (1.4) 44 (65.7) 7 (10.4) 3 (4.5) 34 (52.3) 4 (6.2) 0 Dermatologic 40 (56.3) 3 (4.2) 0 35 (52.2) 2 (3.0) 0 31 (47.7) 1 (1.5) 0 Pruritus 12 (16.9) (7.5) (6.2) 1 (1.5) 0 Rash 20 (28.2) 2 (2.8) 0 9 (13.4) 2 (3.0) 0 6 (9.2) 1 (1.5) 0 Gastrointestinal 21 (29.6) 5 (7.0) 0 16 (23.9) 4 (6.0) 0 11 (16.9) 2 (3.1) 0 Diarrhea 21 (29.6) 5 (7.0) 0 15 (22.4) 3 (4.5) 0 10 (15.4) 2 (3.1) 0 Colitis (3.0) 2 (3.0) AST* 4 (5.6) 2 (2.8) 0 4.(6.0) (3.1) 0 0 ALT* 4 (5.6) 2 (2.8) 0 5 (7.5) 1 (1.5) 0 2 (3.1) 0 0 No grade 4 dermatologic or gastrointestinal iraes were observed Fatal (grade 5) toxic epidermal necrolysis (TEN) was observed in 1 patient in Arm A Hypopituitarism and adrenal Insufficiency were not observed 2 patients experienced grade 1-2 hypothyroidism (1 each in Arm A and B, respectively)
32
33 Cancer Vaccines Cell Based Antigen/peptide based Dendritic cells Tumor cells
34 Vaccines Dendritic cell vaccines Tumor cell vaccines GM-CSF modified tumor cell vaccines Belagenpumatucel-L Protein/peptide vaccines IDM-2101 MAGE A3 vaccine L-BLP25
35
36 Belagenpumatucel-L Belagenpumatucel-L is a nonviral therapeutic vaccine comprised of 4 TGF-β2 antisense gene-modified allogeneic NSCLC cell lines. 2 adenocarcinoma, 1 Squamous cell carcinoma, 1 large cell carcinoma. TGF-β2 production is blocked Irradiated and cryopreserved
37 Phase II study design Cohort x10 7 Cells/injection Key inclusion criteria: Histologically confirmed NSCLC PS 2, stages II-IV (AJCC 6.0) tumor burden of < 125mL R 1:1:1 Cohort 2 2.5x10 7 Cells/injection Stage breakdown: 2 stage II 12 stage IIIA 14 stage IIIB 47 stage IV Cohort 3 5 x 10 7 Cells/injection Intradermal injections administered monthly at 3 clinical sites. Nemunaitis J et al. JCO 2006
38 Safety and Tolerability of Belagenpumatucel-L Adverse events: Injection site reactions Flu-like symptoms All are transient All are grade 2 Slide courtesy of Dan Shawler, PhD
39 Overall Survival by Cohort, All Patients Survival Cohort Median N (months) 1-yr 2-yr 5-yr 7-yr % 21% 17% 20% % 46% 21% 9% % 39% 22% 23% Cohort 1 Cohort 2 Cohort 3 N = 75
40 Overall Survival by Cohort, Stage IIIB/IV Survival Cohort Median N (months) 1-yr 2-yr 5-yr 7-yr % 20% 20% 20% % 40% 17% 7% % 43% 20% 22% Cohort 1 Cohort 2 Cohort 3 N = 61
41 Overall Survival Median N (months) 1-yr 2-yr 5-yr 7-yr SD, PR, or CR % 59% 50% 50% PD % 36% 14% 0% N = 29
42 STOP trial Phase III. Double blind. N=506 Started: October 2008 Expected completion June 2012 R 1:1 Arm A 2.5x10 7 Cells/injection +BSC Arm B Placebo +BSC Key inclusion criteria: Histologically confirmed NSCLC IIIA (T3N2) IIIB IV Maintenance therapy for patients with SD or better following frontline chemotherapy Primary Objective Overall Survival Secondary Objectives: Adverse events Tumor progression Quality of life
43
44 L-BLP 25 MUC 1 (mucin1) glycoprotein antigen Commonly overexpressed in lung cancer and aberrantly glycosylated. L-BLP 25 is a liposomal vaccine containing peptides of the extracellular domain of MUC1 + adjuvant.
45 Phase IIB study design R 1:1 Arm A L-BLP25* Arm B BSC * Patients randomized to vaccine arm received cyclophosphamide 300mg/m2 3 days before vaccine injection N=171 Key inclusion criteria: Histologically confirmed NSCLC Stage IIIB or IV Maintenance therapy for patients with SD or better following frontline chemotherapy Stage breakdown: IIIB Locoregional N=65 IIIB MPE/IV N=106 Injections intradermal, weekly x 8 weeks, followed by q6 weeks till progression C. Butts, J Cancer Res Clin Onc, epub
46 Safety Well tolerated. Most common side effects attributable to vaccine Flu like symptoms Injection site reactions
47 Survival distribution function 1.00 Overall survival, all patients. L-BLP25 (n=88) BSC (n=83) 0.75 HR = 0.745, 95% CI 0.533, Censored observation 0.50 Cohort Median N (months) 3yr BLP % BSC % p Survival time (months) Slide courtesy of Charles Butts 70
48 Survival distribution function 1.00 Overall survival, IIIB (effusion), IV L-BLP25 (n=53) BSC (n=53) 0.75 HR = 0.878, 95% CI 0.587, Censored observation 0.50 Cohort Median N (months) 3yr BLP % BSC % p Survival time (months) Slide courtesy of Charles Butts 70
49 Survival distribution function 1.00 Overall survival, IIIB L-BLP25 (n=35) BSC (n=30) 0.75 HR = 0.548, 95% CI 0.301, Censored observation Cohort Median N (months) 3yr BLP % BSC % p Slide courtesy of Charles Butts Survival time (months) 70
50 START trial Phase III. Double blind. N=1500 Started: December 2006 Completed accrual. R 1:1 Arm A L-BLP 25 +BSC* Arm B Placebo +BSC * Patients randomized to vaccine arm received cyclophosphamide 300mg/m2 3 days before vaccine injection Key inclusion criteria: Histologically confirmed NSCLC Unresectable IIIB Maintenance therapy following curative chemoxrt Primary Objective Overall Survival Secondary Objectives: TTSF TTP Adverse events
51
52 MAGE-A3 Vaccine MAGE melanoma associated antigen Expressed in 35-40% of lung cancers Expression increases with stage and associated with poor prognosis MAGE A3 is a recombinant protein vaccine combined with proprietary immunological adjuvant ASO2B
53 Phase II MAGE A3 study design R 2:1 Arm A MAGE A3 vaccine +BSC Arm B BSC Key inclusion criteria Tumor expresses MAGE Ag Stages IB-II surgically resected 1089 surgical specimens evaluated 363 positive for MAGE 182 entered the trial IB 123 IIA 8 IIB 35 IIIA 16 IM q 3 weeks x 5, followed q3m x 8 Primary endpoint DFI
54 Safety Well tolerated Grade 1 and 2 local or systemic reactions
55 DFS Distribution DFS Distribution Randomized Phase II Trial of MAGE-A3 Vaccine in MAGE-A3+ NSCLC DFI Time From Surgery (Months) MAGE-A3 Placebo HR=0.73 P= DFS MAGE-A3 Placebo HR=0.73 P= Time From Surgery (Months) 27% reduction in relative risk of cancer recurrence following surgery Vansteenkiste. ASCO (abstr 7554)).
56 MAGRIT Phase III double blind. N=2270 Started October 2007 Estimated completion December 2022 R 2:1 Arm A MAGE A3 vaccine +BSC Key inclusion criteria Tumor expresses MAGE Ag Stages I-III surgically resected Stratified by adjuvant therapy received or not Arm B BSC Stage IB of BSC closed Stage IIIA of chemotherapy closed Primary objectives Disease free survival Secondary objective Prospective validation of a predictive gene signature
57 What have we learned over the years Developing immunotherapies is not the same as developing cytotoxics Responses take longer resist RECIST Lower bulk tumors could derive more benefit Generally not toxic Stay tuned for results of phase III trials MAGRIT Resected I-III START and INSPIRE unresectable treated IIIB (locoregional) STOP Treated advanced IIIA Unresectable treated IIIB Controlled IV
58 Immunotherapy agents that I did not cover. GVAX An adenoviral gene-based autologous vaccine TG Vaccinia virus coding for MUC1 and IL2 IDM 2101 Talactoferrin Cadi-05 (TRL2 agonist)
59 Evolution of L. Bazhenova, MD V 1.0 V 2.0 V3.0 V 4.0 Chemotherapist Vocabulary: NSCLC Visual aid: Histopathologist Vocabulary: CK 7, CK 20, TTF-1, CK 5/6, p63 Visual aid: Molecular biologist Vocabulary: EGFR, KRAS, ALK, BRAF, C-MET, PI3K, HER2, MAPK 21, MEK, AKT, FISH, PCR.. Visual aid: Budding Immunologist Vocabulary: THL, CTLA4, MHC, B7, Antigen, TGF, IL-2 Visual aid: V 5.0????????
Slide 1. Slide 2. Slide 3. Immunotherapy in Lung Cancer. Disclosures. Objectives. No disclosures relevant to this talk
Slide 1 Immunotherapy in Lung Cancer Lyudmila Bazhenova, MD Associate Clinical Professor, Moores UCSD Cancer Center Slide 2 Disclosures No disclosures relevant to this talk Slide 3 Objectives Review immune
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationCancer immunology > what should happen (immunosurveillance)
11 th Perspectives in Lung Cancer Vaccines: any expectations? J Vansteenkiste Dept Pulmonology q Cancer immunology, immunotherapy, vaccination q Agents in phase III development o MAGE-A3 A3 ASCI o MUC1
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationΤΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ. Δημήτρης Μαυρουδής Παθολόγος - Ογκολόγος Πανεπιστημιακό Νοσοκομείο Ηρακλείου
ΕΛΙΞΕΙΣ ΣΤΗΝ ΑΝΟΣΟΘΕΡΑΠΕΙ ΤΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ Δημήτρης Μαυρουδής Παθολόγος - Ογκολόγος Πανεπιστημιακό Νοσοκομείο Ηρακλείου LUNG CANCER INCIDENCE LUNG CANCER MORTALITY LUNG CANCER Non-small Cell Lung
More informationAssessment of Efficacy and Immune Related RECIST criteria
Assessment of Efficacy and Immune Related RECIST criteria Dr Kenneth O Byrne Princess Alexandra Hospital and Queensland University of Technology, Brisbane, Australia & Trinity College, Dublin, Ireland
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationTargeting the immune system for management of NSCLC: the revival?
Curr Respir Care Rep (2013) 2:22 39 DOI 10.1007/s13665-012-0038-5 LUNG CANCER (F BARLESI, SECTION EDITOR) Targeting the immune system for management of NSCLC: the revival? Martin Reck & Johan Vansteenkiste
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationInmunoterapia en cáncer de pulmón. Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro
Inmunoterapia en cáncer de pulmón Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Current Therapeutic Landscape for NSCLC Current treatment strategies in NSCLC Various
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine
ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationpresentation session & clinical Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania
Melanoma: highlights from the oral presentation session & clinical science symposium at ASCO 2009 Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania Abstracts to be discussed
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationVaccine Therapy for Cancer
Vaccine Therapy for Cancer Lawrence N Shulman, MD Chief Medical Officer Senior Vice President for Medical Affairs Chief, Division of General Oncology Dana-Farber Cancer Institute Disclosures for Lawrence
More informationThe following protocol information is provided solely to describe how the authors conducted
The following protocol information is provided solely to describe how the authors conducted the research underlying the published report associated with the following article: Phase III Trial of Combined
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationLung cancer is the leading cause of cancer death among
STATE OF THE ART: CONCISE REVIEW Novel Approaches to Improve Patient Outcome Frances A. Shepherd, MD,* Jean-Yves Douillard, MD, PhD, and George R. Blumenschein, Jr., MD Introduction: Non-small cell lung
More informationUpdate on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017
Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single
More informationMelanoma Clinical Trials and Real World Experience
Melanoma Clinical Trials and Real World Experience Paul Lorigan University of Manchester Manchester, UK www.christie.nhs.uk/melanoma Melanoma Bridge, Naples 214 New Benchmarks for Phase II Trials OS at
More informationCheckpoint-Inhibitoren beim Lungenkarzinom. Dr. Helge Bischoff Thoraxklinik Heidelberg
Checkpoint-Inhibitoren beim Lungenkarzinom Dr. Helge Bischoff Thoraxklinik Heidelberg Survival (%) First-Line: Polychemotherapy vs 9387 patients 778 patients in studies with platinum chemotherapy 1-year
More informationThis item is the archived peer-reviewed author-version of:
This item is the archived peer-reviewed author-version of: Immunotherapy : is a minor god yet in the pantheon of treatments for lung cancer? Reference: Rolfo Christian, Sortino Giovanni, Smits Evelien,
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationAdjuvant Therapy of High Risk Melanoma
Adjuvant Therapy of High Risk Melanoma William Sharfman, MD, FACP Associate Professor of Oncology and Dermatology Johns Hopkins University School of Medicine July 5, 2012 Adjuvant options for Stage IIB/C
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationImmunotherapy in lung cancer. Saurabh maji
Immunotherapy in lung cancer Saurabh maji Worldwide, lung cancer is the most common cause of cancerrelated deaths Small cell lung cancer (SCLC) presents with widespread disease at the time of diagnosis,
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More informationImmunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know
Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT
PAGE 175 PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN BY PRODUCT Summary of risk management plan for pembrolizumab This is a summary of the risk management plan (RMP) for pembrolizumab. The RMP details
More informationImmunotherapeutic Approaches in the Treatment of NSCLC. Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary
01 Immunotherapeutic Approaches in the Treatment of NSCLC Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary Outline 02 Review the concept and evolution of immunotherapy in the treatment of cancer Discuss
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationCancer Vaccines and Cytokines. Elizabeth A. Mittendorf, MD, PhD Assistant Professor Department of Surgical Oncology
Cancer Vaccines and Cytokines Elizabeth A. Mittendorf, MD, PhD Assistant Professor Department of Surgical Oncology Disclosures I serve as the PI on a phase III trial sponsored by Galena BioPharma investigating
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationASCO 2010 Update. Advanced Non Small Cell Lung Cancer 7/13/2010. Background. Background. ALK fusion protein. ALK-positive NSCLC
The American Society of Clinical Oncology (ASCO) 2010 Annual Meeting, which returned to Chicago this year, held June 4-8. ASCO 2010 Update Advancing quality through innovation Suphat Subongkot, Pharm.D.,BCPS,
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationSYNOPSIS. Final Clinical Study Report for Study CA Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product:
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: Anti-CTLA-4 Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS
More informationMalignant pleural Mesothelioma: A Year In Review
Malignant pleural Mesothelioma: A Year In Review Rabab Gaafar,MD Prof. Medical Oncology NCI Cairo University National Cancer Institute Conference 2015 ASCO news in Mesothelioma Introduction ASCO news second
More informationSummary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationLong term survival in EGFR positive NSCLC patient. Dr.ssa G. Zago Oncologia Medica 2 Istituto Oncologico Veneto, IOV
Long term survival in EGFR positive NSCLC patient Dr.ssa G. Zago Oncologia Medica 2 Istituto Oncologico Veneto, IOV Medical history and diagnosis Male, caucasian 60 years old Former smoker (stop > 15 years)
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationCancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment
Cancer Immunotherapy: Exploring the Role of Novel Agents in Cancer Treatment Patrick Medina, Pharm.D., BCOP Professor The University of Oklahoma College of Medicine Stephenson Cancer Center Faculty Disclosure
More informationBest Practices in the Treatment and Management of Metastatic Melanoma. Melanoma
Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More informationMonthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care Lung Cancer: Advanced Disease March 8, 2016 Jae Kim, MD City of Hope Comprehensive Cancer Center Karen Reckamp,
More informationBreast Cancer Immunotherapy. Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy
Breast Cancer Immunotherapy Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy Conflict of Interest I have the following financial relationships to disclose:
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationImmunotherapies in Lung Cancer: Can We Deliver on the Promise? (Part 2) with Drs. Ramaswamy Govindan & Julie Brahmer
Immunotherapies in Lung Cancer: Can We Deliver on the Promise? (Part 2) with Drs. Ramaswamy Govindan & Julie Brahmer Cancer Immunotherapy Disclosure of Financial Relationships Consulting: Bristol Meyers
More informationNew Therapeutic Approaches to Malignant Melanoma
2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationEstado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationGSK VACCINES: BUILDING A THERAPEUTIC PORTFOLIO
GSK VACCINES: BUILDING A THERAPEUTIC PORTFOLIO Vincent Brichard, MD Vice President & Head of Immunotherapeutics, GSK Biologicals Immunotherapy in action Cytolytic T Lymphocyte (CTL) Tumour cell Killed
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationRuolo emergente dell immunoterapia nello stadio III. Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy)
Ruolo emergente dell immunoterapia nello stadio III Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy) Disclosures Advisory Boards / Honoraria / Speakers fee / Consultant for: MSD,
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More information